The efficacy and safety of anti-IGF1R antibodies have been explored in a wide variety of malignancies including bone and soft tissue sarcomas, squamous cell carcinoma, pancreatic cancer, lymphomas, colorectal cancer, and non-small cell lung cancer (NSCLC) [33]–[38]. The gene discussed is IGF1R; the disease is familial pancreatic carcinoma.